AP
ICPT

AtonRa Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

AtonRa Partners’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,581
Closed -$206K – 128
2023
Q2 		$206K Sell
18,581
-1,251
-6% -$17.4K 0.32% 116
2023
Q1 		$266K Sell
19,832
-1,932
-9% -$33.4K 0.39% 109
2022
Q4 		$269K Sell
21,764
-5,886
-21% -$83.3K 0.34% 104
2022
Q3 		$386K Buy
27,650
+3,233
+13% +$52.1K 0.38% 107
2022
Q2 		$337K Buy
+24,417
New +$391K 0.31% 117

Other funds holding ICPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

AtonRa Partners's ICPT Position: Q3 2023 in Review

AtonRa Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 18,581 shares — an estimated $206K sold.

AtonRa Partners first reported a position in ICPT in Q2 2022 and held it in 5 quarters. The position peaked at $386K in Q3 2022. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

  • AtonRa Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • AtonRa Partners sold 18,581 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $206K.
  • AtonRa Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2022 and held it in 5 quarters.
  • AtonRa Partners's Intercept Pharmaceuticals, Inc. position peaked at $386K in Q3 2022.
  • 146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on AtonRa Partners's 13F filing for Q3 2023, filed 25 Oct 2023.